{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:14:01Z","timestamp":1787242441970,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) are useful in peptic ulcer prevention, their efficacy in preventing other gastrointestinal bleeding remains unclear. This study aimed to identify the status of gastrointestinal bleeding in the modern era when PPIs are widely used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included patients who underwent percutaneous coronary intervention (PCI) between 2018 and 2019 at two high-volume centers. Patients were categorized based on whether they experienced gastrointestinal bleeding within 2 years of PCI into groups A (patients who experienced gastrointestinal bleeding within 2 years after PCI) and B (patients who did not experience gastrointestinal bleeding).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Groups A and B included 21 (4.1%) and 494 (95.9%) patients, respectively (a total of 515 patients). Age at the initial PCI (77.8\u00b12.4 and 72.0\u00b10.5 years in groups A and B, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), weight (53.8\u00b13.2 and 61.8\u00b10.7\u00a0kg in groups A and B, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and concomitant warfarin use (14.3% and 2.0% in groups A and B, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005) were significantly different between the groups. The high bleeding risk rate (90.5% and 47.6% in groups A and B, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001) was significantly different between the groups. A total of 95.9% of patients were taking PPIs or PCAB without significant differences between the groups. However, only one patient, who was taking steroids, had a gastric ulcer during PCAB treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Acid-related upper gastrointestinal bleeding is largely controlled by PPIs in post-PCI patients. Furthermore, the risk factors for non-acid-related bleeding include older age, lower weight, and concomitant warfarin use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-024-03269-w","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T05:02:07Z","timestamp":1716267727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Widespread use of proton pump inhibitors or potassium-competitive acid blocker has changed the status of gastrointestinal bleeding in patients with ischemic heart disease: real-world data from high volume centers"],"prefix":"10.1186","volume":"24","author":[{"given":"Shun","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sanomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Hakoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nagamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Hoshiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"3269_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jacc.2009.07.019","volume":"54","author":"E Nikolsky","year":"2009","unstructured":"Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute catheterization and urgent intervention triage strategy) trial. J Am Coll Cardiol. 2009;54:1293\u2013302.","journal-title":"J Am Coll Cardiol"},{"key":"3269_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2020.02.012","volume":"76","author":"K Tsujita","year":"2020","unstructured":"Tsujita K, Deguchi H, Uda A, et al. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study. J Cardiol. 2020;76:51\u20137.","journal-title":"J Cardiol"},{"key":"3269_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/hel.12110","volume":"19","author":"J Ueda","year":"2014","unstructured":"Ueda J, Gosho M, Inui Y, et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter. 2014;19:105\u201310.","journal-title":"Helicobacter"},{"key":"3269_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kimura K, Kimura T, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84:831\u201365.","journal-title":"Circ J"},{"key":"3269_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1254\/jphs.FP0071606","volume":"106","author":"Y Takeuchi","year":"2008","unstructured":"Takeuchi Y, Takahashi M, Fuchikami J. Vulnerability of gastric mucosa to prednisolone in rats chronically exposed to cigarette smoke. J Pharmacol Sci. 2008;106:585\u201392.","journal-title":"J Pharmacol Sci"},{"key":"3269_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","volume":"83","author":"K Kimura","year":"2019","unstructured":"Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085\u2013196.","journal-title":"Circ J"},{"key":"3269_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/hrt.2010.217547","volume":"97","author":"JM Scheiman","year":"2011","unstructured":"Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97:797\u2013802.","journal-title":"Heart"},{"key":"3269_CR8","doi-asserted-by":"publisher","first-page":"e27411","DOI":"10.1097\/MD.0000000000027411","volume":"100","author":"D Lee","year":"2021","unstructured":"Lee D, Kim JS, Kim BJ, et al. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention. Med (Baltim). 2021;100:e27411.","journal-title":"Med (Baltim)"},{"key":"3269_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jjcc.2020.08.008","volume":"77","author":"M Nakamura","year":"2021","unstructured":"Nakamura M, Yamashita T, Hayakawa A, et al. Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: a comparative study. J Cardiol. 2021;77:186\u201394.","journal-title":"J Cardiol"},{"key":"3269_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3164\/jcbn.18-16","volume":"63","author":"A Hara","year":"2018","unstructured":"Hara A, Ota K, Takeuchi T, et al. Dual anti-platelet therapy does not affect the incidence of LDA-induced small intestinal mucosal injury in patients after percutaneous coronary intervention for coronary stenosis: a multicenter cross-sectional study. J Clin Biochem Nutr. 2018;63:224\u20139.","journal-title":"J Clin Biochem Nutr"},{"key":"3269_CR11","doi-asserted-by":"crossref","unstructured":"Zhou M, Zhang J, Liu J et al. Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual anti-platelet therapy. Mayo Clin Proc. 2022;97:682\u201392.","DOI":"10.1016\/j.mayocp.2021.11.037"},{"key":"3269_CR12","doi-asserted-by":"publisher","first-page":"7750","DOI":"10.4103\/jfmpc.jfmpc_1298_22","volume":"11","author":"G Ray","year":"2022","unstructured":"Ray G. Incidence and outcome of gastrointestinal bleeding in patients receiving aspirin with or without clopidogrel over 10 years. An observational study. J Family Med Prim Care. 2022;11:7750\u20135.","journal-title":"J Family Med Prim Care"},{"key":"3269_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"3269_CR14","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1002\/deo2.60","volume":"2","author":"W Hatta","year":"2021","unstructured":"Hatta W, Koike T, Abe H, et al. Recent approach for preventing complications in upper gastrointestinal endoscopic submucosal dissection. DEN open. 2021;2:e60.","journal-title":"DEN open"},{"key":"3269_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00228-021-03167-0","volume":"77","author":"H Tsujimoto","year":"2021","unstructured":"Tsujimoto H, Hirata Y, Ueda Y, et al. Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin. Eur J Clin Pharmacol. 2021;77:1639\u201348.","journal-title":"Eur J Clin Pharmacol"},{"key":"3269_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14740338.2023.2136163","volume":"22","author":"T Kawai","year":"2023","unstructured":"Kawai T, Suzuki C, Honda Y, et al. Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study. Expert Opin Drug Saf. 2023;22:425\u201331.","journal-title":"Expert Opin Drug Saf"},{"key":"3269_CR17","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41598-024-51682-8","volume":"14","author":"CC Chang","year":"2024","unstructured":"Chang CC, Chou YC, Chang JY, et al. Effects of treatment with clopidogrel with or without proton pump inhibitor omeprazole on the risk of ischemic stroke: a nationwide cohort study. Sci Rep. 2024;14:1686.","journal-title":"Sci Rep"},{"key":"3269_CR18","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.3390\/jcm11216382","volume":"11","author":"M Brigida","year":"2022","unstructured":"Brigida M, Di Caro S, Petruzziello C, et al. Vitamin-K antagonists vs. direct oral anticoagulants on severity of upper gastrointestinal bleeding: a retrospective analysis of Italian and UK Data. J Clin Med. 2022;11:6382.","journal-title":"J Clin Med"},{"key":"3269_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14740338.2017.1325870","volume":"16","author":"A Lanas-Gimeno","year":"2017","unstructured":"Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf. 2017;16:673\u201385.","journal-title":"Expert Opin Drug Saf"},{"key":"3269_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4292\/wjgpt.v7.i3.440","volume":"7","author":"K Kinjo","year":"2016","unstructured":"Kinjo K, Matsui T, Hisabe T, et al. Increase in colonic diverticular hemorrhage and confounding factors. World J Gastrointest Pharmacol Ther. 2016;7:440\u20136.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"3269_CR21","first-page":"701","volume":"13","author":"GE Pate","year":"2004","unstructured":"Pate GE, Chandavimol M, Naiman SC, et al. Heyde\u2019s syndrome: a review. J Heart Valve Dis. 2004;13:701\u201312.","journal-title":"J Heart Valve Dis"},{"key":"3269_CR22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/archinte.163.15.1821","volume":"163","author":"P Batur","year":"2003","unstructured":"Batur P, Stewart WJ, Isaacson JH. Increased prevalence of aortic stenosis in patients with arteriovenous malformations of the gastrointestinal tract in Heyde syndrome. Arch Intern Med. 2003;163:1821\u20134.","journal-title":"Arch Intern Med"},{"key":"3269_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3164\/jcbn.21-136","volume":"70","author":"A Hakoda","year":"2022","unstructured":"Hakoda A, Takeuchi T, Kojima Y, et al. Risk factors and prediction of bleeding after gastric endoscopic submucosal dissection in patients on antithrombotic therapy: newly developed bleeding prediction application software, SAMURAI model. J Clin Biochem Nutr. 2022;70:189\u201396.","journal-title":"J Clin Biochem Nutr"},{"key":"3269_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/gutjnl-2019-319926","volume":"70","author":"W Hatta","year":"2021","unstructured":"Hatta W, Tsuji Y, Yoshio T, et al. Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score. Gut. 2021;70:476\u201384.","journal-title":"Gut"},{"key":"3269_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apt.15641","volume":"51","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Furuta T, Fujiwara Y, et al. Randomised trial of acid inhibition by Vonoprazan 10\/20\u00a0mg once daily vs rabeprazole 10\/20\u00a0mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020;51:534\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"3269_CR26","doi-asserted-by":"publisher","first-page":"10477","DOI":"10.3748\/wjg.v22.i48.10477","volume":"22","author":"A Lu\u00e9","year":"2016","unstructured":"Lu\u00e9 A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: balancing risks and benefits. World J Gastroenterol. 2016;22:10477\u201381.","journal-title":"World J Gastroenterol"},{"key":"3269_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3164\/jcbn.16-49","volume":"59","author":"K Ota","year":"2016","unstructured":"Ota K, Takeuchi T, Nouda S, et al. Determination of the adequate dosage of rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-induced gastrointestinal mucosal injury. J Clin Biochem Nutr. 2016;59:231\u20137.","journal-title":"J Clin Biochem Nutr"},{"key":"3269_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12876-018-0923-7","volume":"19","author":"K Ota","year":"2019","unstructured":"Ota K, Takeuchi T, Kojima Y, et al. Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal mucosal injury: a randomized, double-blind, pilot study. BMC Gastroenterol. 2019;19:4.","journal-title":"BMC Gastroenterol"},{"key":"3269_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00535-015-1055-2","volume":"50","author":"N Nagata","year":"2015","unstructured":"Nagata N, Niikura R, Aoki T, et al. Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. J Gastroenterol. 2015;50:1079\u201386.","journal-title":"J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03269-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T05:10:49Z","timestamp":1716268249000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03269-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3269"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03269-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the 1975 Declaration of Helsinki (revised in 1983). The study protocol was approved by the Institutional Review Board of Osaka Medical and Pharmaceutical University (approval number: 2021-029). The study was publicized on the bulletin boards and websites of each facility to ensure that participants had the opportunity to refuse participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}